Here, we present results from a national approach of thorough biological evaluation of all neuroblastomas and joint clinicobiological assessment of children with relapsed or refractory neuroblastoma for early implementation of targeted therapy using the third generation ALK-inhibitor lorlatinib for ALK-driven tumors. The gene discussed is ALK; the disease is neuroblastoma.